Allurion Technologies Inc ALUR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Allurion Receives Continued Listing Standards Notice from NYSE
-
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
-
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors
-
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program
-
Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial
-
Allurion Receives Continued Listing Standards Notice from NYSE
-
Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024
Trading Information
- Previous Close Price
- $0.65
- Day Range
- $0.62–0.65
- 52-Week Range
- $0.55–5.34
- Bid/Ask
- $0.61 / $0.65
- Market Cap
- $41.36 Mil
- Volume/Avg
- 37,934 / 312,834
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- —
- Total Number of Employees
- 24
- Website
- https://www.allurion.com
Comparables
Valuation
|
Metric
|
ALUR
|
IRTC
|
603301
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 21.66 |
Price/Book Value | — | 22.54 | 1.05 |
Price/Sales | 0.50 | 4.12 | 1.49 |
Price/Cash Flow | — | 33.96 | 9.03 |
Price/Earnings
ALUR
IRTC
603301
Financial Strength
|
Metric
|
ALUR
|
IRTC
|
603301
|
|---|---|---|---|
Quick Ratio | 1.38 | 6.61 | 1.57 |
Current Ratio | 1.71 | 6.92 | 2.24 |
Interest Coverage | −3.58 | −16.85 | 5.28 |
Quick Ratio
ALUR
IRTC
603301
Profitability
|
Metric
|
ALUR
|
IRTC
|
603301
|
|---|---|---|---|
Return on Assets (Normalized) | −64.81% | −17.06% | 1.65% |
Return on Equity (Normalized) | — | −63.36% | 2.34% |
Return on Invested Capital (Normalized) | — | −20.40% | 1.91% |
Return on Assets
ALUR
IRTC
603301
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Jnqrggxdh | Rnhkl | $195.9 Bil | |||
| Stryker Corp
SYK
| Kcppxxgwy | Tfdf | $137.0 Bil | |||
| Boston Scientific Corp
BSX
| Wytrckfj | Tlwlzg | $123.0 Bil | |||
| Medtronic PLC
MDT
| Tshdjrghf | Dyrdbq | $114.7 Bil | |||
| Edwards Lifesciences Corp
EW
| Fznqsyhfm | Kjkzpg | $39.4 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Wtbp | Pthd | $29.1 Bil | |||
| DexCom Inc
DXCM
| Hrvnpvysq | Vqkxv | $26.7 Bil | |||
| Steris PLC
STE
| Kkdxnfsdc | Znnxlp | $23.3 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Fhgdqbcmbp | Lzxh | $21.7 Bil | |||
| Insulet Corp
PODD
| Zpmgymgzpk | Fnxwc | $16.7 Bil |
United States